Scott M C MC - OmicsDI

Show results for

Unknown (792)
Genomics (36)
Transcriptomics (14)
Proteomics (10)
Metabolomics (3)
Genomic (1)

Organisms

Homo sapiens (48)
Mus musculus (6)
Canis lupus familiaris (2)
Escherichia coli K-12 (1)

Repository

EGA (34)
biostudies-arrayexpress (16)
pride (7)
MassIVE (3)
MetaboLights (3)
dbGaP (1)

Tissue

Blood (1)
Cell culture (1)
Mast cell (1)
T cell (1)

Disease

Disease free (1)
Neurodevelopmental delay (1)

Technology Type

Mass Spectrometry (7)
Bottom-up proteomics (4)
Shotgun proteomics (3)
Mass spectrometry (2)
AB SOLiD 4 System, Illumina HiSeq 2500, Illumina HiSeq 2000, AB SOLiD System 3.0 (1)
Illumina Genome Analyzer IIx, Illumina HiSeq 2000 (1)
Mass spectrometry assay (1)
NMR spectroscopy assay (1)
Affinity proteomics (1)
Data-dependent acquisition (1)
Data-independent acquisition (1)
DiaPASEF (1)

Instrument Platform

Illumina HiSeq 2500 (3)
NextSeq 500 (2)
Q Exactive (2)
Illumina MiSeq (1)
Orbitrap Fusion (1)
Q Exactive Plus (1)
TripleTOF 5600 (1)
Liquid Chromatography MS - Negative (LC-MS (NEG)) (1)
Liquid Chromatography MS - Positive (LC-MS (POS)) (1)
Liquid Chromatography MS - alternating - reverse phase (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - hilic (1)
Nuclear Magnetic Resonance (NMR) - (1)

Publication Date

2025 (7)
2024 (4)
2016 (4)
2019 (3)
2023 (3)
2012 (2)
2015 (1)
2014 (1)
2013 (1)
2011 (1)
2010 (1)
2017 (1)

CHEBI ID

CHEBI:15676 (2)
CHEBI:15727 (2)
CHEBI:15756 (2)
CHEBI:16010 (2)
CHEBI:16525 (2)
CHEBI:16704 (2)
CHEBI:16755 (2)
CHEBI:16919 (2)
CHEBI:16990 (2)
CHEBI:17154 (2)
CHEBI:17687 (2)
CHEBI:17716 (2)
CHEBI:18089 (2)
CHEBI:18132 (2)
CHEBI:18257 (2)
CHEBI:27471 (2)
CHEBI:27823 (2)
CHEBI:28834 (2)
CHEBI:36274 (2)
CHEBI:48430 (2)
CHEBI:55328 (2)
CHEBI:68567 (2)
CHEBI:70958 (2)
CHEBI:71466 (2)
CHEBI:9410 (2)
CHEBI:100241 (1)
CHEBI:10033 (1)
CHEBI:10072 (1)
CHEBI:10125 (1)
CHEBI:101278 (1)

Metabolite Name

(R)-3-hydroxybutyrylcarnitine (1)
1,3,7-trimethylurate (1)
1,3-dimethylurate (1)
1,6-anhydroglucose (1)
1,7-dimethylurate (1)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)* (1)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)* (1)
1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* (1)
1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)* (1)
1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)* (1)
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* (1)
1-(1-enyl-palmitoyl)-GPE (P-16:0)* (1)
1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)* (1)
1-(1-enyl-stearoyl)-GPE (P-18:0)* (1)
1-Methylhistidine (1)
1-arachidonoyl-GPA (20:4) (1)
1-arachidonoyl-GPI (20:4)* (1)
1-lignoceroyl-GPC (24:0) (1)
1-linolenoyl-GPC (18:3)* (1)
1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6)* (1)
1-linoleoyl-GPC (18:2) (1)
1-linoleoyl-GPE (18:2)* (1)
1-linoleoyl-GPI (18:2)* (1)
1-methyl-4-imidazoleacetate (1)
1-methylhistidine (1)
1-methylnicotinamide (1)
1-methylurate (1)
1-methylxanthine (1)
1-myristoyl-2-palmitoyl-GPC (14:0/16:0) (1)
1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6)* (1)

Study type

Transcription profiling by array (7)
CUT&RUN (2)
RNA-seq of total RNA (2)
RNA-seq of coding RNA (2)
Comparative genomic hybridization by array (1)
ChIP-seq (1)
Methylation profiling by high throughput sequencing (1)

Release Date

2022 (92)
2021 (91)
2023 (71)
2024 (70)
2020 (63)
2019 (51)
2015 (50)
2025 (49)
2017 (47)
2018 (43)
2016 (36)
2014 (35)
2012 (28)
2013 (22)
2011 (18)
2010 (13)
2009 (11)
2008 (8)
2026 (4)
2004 (3)
2007 (1)
2006 (1)
2005 (1)

Lab affiliation

University of Victoria (2)
95 Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, 31077, France (1)
Centre for Proteome Research, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7ZB, U.K. (1)
Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, UK (1)
Head, Inflammation Division Professor and NHMRC Leadership Fellow Walter and Eliza Hall Institute of Medical Research 1G Royal Parade Parkville, VIC 3052, Australia (1)
Head, Inflammation Division Professor and NHMRC Leadership Fellow Walter and Eliza Hall Institute of Medical Research 1G Royal Parade Parkville, VIC 3052, Australia (lab head) (1)

Previous page
1 / 86
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 86
Next page

Sort by:

Relevance

Page size

Comparison of the MC-LR and MC-RR effects on Caco-2 cells

Microcystins (MCs) are cyclic hepatotoxins produced worldwide by various species of cyanobacteria. Their structure includes two variable amino acids (AAs) and most of the studies focused on the most toxic variant: the microcystin LR (MC-LR). However, more than 80 MC variants have been described to d...

ORGANISM(S): Homo sapiens

2012-12-31 | E-GEOD-29861 | biostudies-arrayexpress

Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.

Not available

S-EPMC5033697 | biostudies-literature

Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2^-/- mice and human primary sclerosing cholangitis.

Not available

S-EPMC6214746 | biostudies-literature

Dicaesium tetra-chlorido-dioxido-plutonate(VI).

Not available

S-EPMC2914883 | biostudies-literature

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML

MLL-fusion proteins can induce acute myeloid leukemias (AML) from either hematopoietic stem cells (HSC) or granulocyte macrophage progenitors (GMP), but it remains unclear if the cell of origin influences the biology of the resultant leukemia. MLL-AF9 transduced single HSC or GMP could be continuous...

ORGANISM(S): Mus musculus

2013-01-09 | E-GEOD-43333 | biostudies-arrayexpress

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights

Quantitative chemical proteomic profiling of phosphoprotein phosphatases

We have developed a chemical proteomic strategy for the systematic interrogation of endogenous phosphoprotein phosphatases (PPP) and their interacting proteins, including regulatory and scaffolding subunits, and substrates (the 'PPPome'). PPPs are captured using an immobilized non-selective PPP inhi...

ORGANISM(S): Neurospora Crassa (ncbitaxon:5141) Candida Albicans (ncbitaxon:5476) Saccharomyces Cerevisiae (ncbitaxon:4932) Homo Sapiens (ncbitaxon:9606) Mus Musculus (ncbitaxon:10090) Schizosaccharomyces Pombe (ncbitaxon:4896)

2017-07-07 | MSV000081226 | MassIVE

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Not available

S-EPMC5455603 | biostudies-literature

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Not available

S-EPMC4672027 | biostudies-literature

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.

Not available

S-EPMC6058354 | biostudies-literature